BAX News and Press, Baxter International Inc. From 02/25/24

2024-02-25 06:27:50 ET Summary A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates. Companies with upcoming pay dates. Introduction The D...

2024-02-23 10:45:00 ET Summary Medical equipment and device manufacturer Baxter International was another Ozempic casualty. BAX slid 15% the day Novo Nordisk concluded trials showing Ozempic  slowed the progression of chronic kidney disease. The multiple on BAX collapsed ...

2024-02-21 17:01:53 ET More on Baxter, Spectral Diagnostics, etc. Baxter: Market-Leading Medical Supplier With Lots In The Pipeline Baxter International Inc. 2023 Q4 - Results - Earnings Call Presentation Baxter International Inc. (BAX) Q4 2023 Earnings Call Transcri...

TORONTO, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, is pleased to announce an extension to its supply and distribution...

2024-02-21 04:34:18 ET Summary Baxter International gets its buy rating from December reaffirmed, agreeing with today's bullish consensus from SA analysts and Wall Street. Positive drivers of the bull call include recent Q4 performance, declining debt, innovative new products in t...

TORONTO, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced a major milestone by reaching its Interim Enrollme...

2024-02-13 00:45:30 ET More on Baxter Baxter International: A Cheap Big Pharma Stock With Improving Earnings And +3% Dividend Yield Baxter reports Q4 results; initiates Q1 and FY24 outlook Read the full article on Seeking Alpha For further details see: Ba...

2024-02-12 12:30:03 ET Barclays analyst issues OVERWEIGHT recommendation for BAX on February 12, 2024 12:00PM ET. The previous analyst recommendation was Overweight. BAX was trading at $39.915 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...

2024-02-10 07:00:00 ET Summary The market is at record highs and some stocks are going parabolic. Many investors fear another dangerous tech bubble could crash the market. Fortunately, it's always a market of stocks, not a stock market. World-class blue chips always are trading at...

2024-02-08 17:05:40 ET BAX has experienced positive revenue growth in recent years, driven by international demand, product launches, increased demand for cardiology products, and improved availability of component parts. To enhance operational efficiency, the company has undertaken actio...